Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389084 | 1.00 | PARP1 (0.60) | PARP1PRAP1 | |
| SCHEMBL3385598 | 0.94 | PARP1 (0.58) | PARP1PRAP1 | |
| SCHEMBL3385596 | 0.94 | PARP1 (0.58) | PARP1PRAP1 | |
| SCHEMBL3390228 | 0.94 | PARP1 (0.57) | PARP1PRAP1 | |
| SCHEMBL3390232 | 0.94 | PARP1 (0.57) | PARP1PRAP1 | |
| SCHEMBL14573238 | 0.90 | PARP1 (0.47) | PARP1 | |
| SCHEMBL3390450 | 0.86 | PARP1 (0.57) | PARP1 | |
| SCHEMBL3390454 | 0.86 | PARP1 (0.57) | PARP1 | |
| SCHEMBL3389573 | 0.84 | PARP1 (0.67) | PARP1 | |
| SCHEMBL3388659 | 0.82 | PARP1 (0.71) | PARP1PRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501822-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1501822-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2005-02-02 | — | — | EP | disclosed |
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2003093261-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023968-A1 | Phthalazinone derivatives, and their use as pharmaceuticals. In particular, the present as enzyme inhibitors | PARP1, PARP2, PARP15 | PARP1 1/4885PRAP1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.